Company: CERO
Filing Date: 2025-02-07
Form Type: 424B3
Source: 0001213900-25-011071
Chunk: 92

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-02-07
Form: 424B3
Chunk 92
---
 markets;                                                                      |

| ● | any patents that we obtain,                                                                                                       
 or are licensed to us, may not provide us with any competitive advantages or protection against competitors, or may be challenged 
 by third parties;                                                                                                                 |

| ● | we cannot predict the scope                                                                                                        
 of protection of any patent issuing based on our patent applications, including whether the patent applications that we own or may 
 in-license in the future will result in issued patents with claims that cover our product candidates or uses thereof in the United 
 States or in other foreign countries;                                                                                              |

| ● | if we attempt to enforce                                                                        
 our patents, a court may hold that our patents are not invalid, unenforceable or not infringed; |

| ● | we may not develop additional                 
 proprietary technologies that are patentable; |

| ● | we may need to initiate                                                                                                          
 litigation or administrative proceedings to enforce and/or defend our patent rights which will be costly whether we win or lose; |

| ● | we may choose not to file                                                                                                                    
 a patent in order to maintain certain trade secrets or know-how, and a third party may subsequently file a patent covering such intellectual 
 property;                                                                                                                                    |

| ● | we may be required to change,                                                                                                        
 redesign or stop using trademarks, service marks, domain names, logos, trade names and other identifiers that we own or use to avoid 
 infringing the rights of third parties;                                                                                              |

| ● | we may fail to adequately                
 protect and police our trade secrets; or |

| ● | the patents of others may                                                                                                               
 have an adverse effect on our business, including if others obtain patents claiming subject matter similar to or improving that covered 
 by our patents and patent applications.                                                                                                 |

Should any of these events
occur, they could significantly harm our business, results of operations and prospects.

Without patent protection
on the composition of matter of our product candidates, our ability to assert our patents to stop others from using or selling our product
candidates in a non-pharmaceutically acceptable formulation may be limited.

Due to the patent laws of
a country, or the decisions of a patent examiner in a country, or our own filing strategies, we may not obtain patent coverage for all
of our product candidates or methods involving these candidates in parent patent applications. We may have to pursue divisional patent
applications or continuation patent applications in the United States and other countries to obtain claim coverage for inventions
which were disclosed but not claimed in parent patent applications.

Moreover, it